Three melanoma cell lines expressing different levels of TRAIL-R2 (Me15, Me41, and Me64) and two breast cancer cell lines (MDA-MB-468 and BT-474) totally negative for the receptor (Table 2) were used to confirm the correct binding of our antibody. The gene discussed is TNFRSF10B; the disease is breast cancer.